Liccardo F, Luini A, Di Martino R. Endomembrane-based signaling by GPCRs and G-proteins. Cells. 2022;11(3):528.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Calebiro D, Koszegi Z, Lanoiselée Y, Miljus T, O’Brien S. G protein-coupled receptor-G protein interactions: a single-molecule perspective. Physiol Rev. 2021;101(3):857–906.

Article  PubMed  CAS  Google Scholar 

Zalewska M, Siara M, Sajewicz W. G protein-coupled receptors: abnormalities in signal transmission, disease states and pharmacotherapy. Acta Pol Pharm. 2014;71(2):229–43.

PubMed  Google Scholar 

Li J, Ge Y, Huang JX, Strømgaard K, Zhang X, Xiong XF. Heterotrimeric G proteins as therapeutic targets in drug discovery. J Med Chem. 2020;63(10):5013–30.

Article  PubMed  CAS  Google Scholar 

Afzal MS. G proteins: binary switches in health and disease. Cent Eur J Immunol. 2020;45(3):364–7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kostenis E, Pfeil EM, Annala S. Heterotrimeric Gq proteins as therapeutic targets? J Biol Chem. 2020;295(16):5206–15.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kamato D, Mitra P, Davis F, Osman N, Chaplin R, Cabot PJ, Afroz R, Thomas W, Zheng W, Kaur H, Brimble M, Little PJ. Ga q proteins: molecular pharmacology and therapeutic potential. Cell Mol Life Sci. 2017;74(8):1379–90.

Article  PubMed  CAS  Google Scholar 

Wang D, Zhang Y, He Y, Li Y, Lund FE, Shi G. The deficiency of Gαq leads to enhanced T-cell survival. Immunol Cell Biol. 2014;92(9):781–90.

Article  PubMed  CAS  Google Scholar 

Wang D, Liu Y, Li Y, He Y, Zhang J, Shi G. G α q regulates the development of rheumatoid arthritis by modulating Th1 differentiation. Mediators Inflamm. 2017;2017:4639081.

Article  PubMed  PubMed Central  Google Scholar 

Liu Y, Wang D, Li F, Shi G. Gαq controls rheumatoid arthritis via regulation of Th17 differentiation. Immunol Cell Biol. 2015;93(7):616–24.

Article  PubMed  CAS  Google Scholar 

Li Y, Huang H, Liu B, Zhang Y, Pan X, Yu XY, Shen Z, Song YH. Inflammasomes as therapeutic targets in human diseases. Signal Transduct Target Ther. 2021;6(1):247.

Huang Y, Xu W, Zhou R. NLRP3 inflammasome activation and cell death. Cell Mol Immunol. 2021;18(9):2114–27.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20(13):3328.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 2019;10(2):128.

Article  PubMed  PubMed Central  Google Scholar 

Kong R, Sun L, Li H, Wang D. The role of NLRP3 inflammasome in the pathogenesis of rheumatic disease. Autoimmunity. 2022;55(1):1–7.

Article  PubMed  CAS  Google Scholar 

Li Z, Guo J, Bi L. Role of the NLRP3 inflammasome in autoimmune diseases. Biomed Pharmacother. 2020;130: 110542.

Article  PubMed  CAS  Google Scholar 

Glukhova A, Draper-Joyce CJ, Sunahara RK, Christopoulos A, Wootten D, Sexton PM. Rules of engagement: GPCRs and G proteins. ACS Pharmacol Transl Sci. 2018;1(2):73–83.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ricart-Ortega M, Font J, Llebaria A. GPCR photopharmacology. Mol Cell Endocrinol. 2019;488:36–51.

Article  PubMed  CAS  Google Scholar 

Zhang H, Nielsen AL, Strømgaard K. Recent achievements in developing selective Gq inhibitors. Med Res Rev. 2020;40(1):135–57.

Article  PubMed  CAS  Google Scholar 

Blevins HM, Xu Y, Biby S, Zhang S. The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases. Front Aging Neurosci. 2022;14: 879021.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Coll RC, Schroder K, Pelegrín P. NLRP3 and pyroptosis blockers for treating inflammatory diseases. Trends Pharmacol Sci. 2022;43(8):653–68.

Article  PubMed  CAS  Google Scholar 

Zhang Y, Yang W, Li W, Zhao Y. NLRP3 inflammasome: checkpoint connecting innate and adaptive immunity in autoimmune diseases. Front Immunol. 2021;12: 732933.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shen HH, Yang YX, Meng X, Luo XY, Li XM, Shuai ZW, Ye DQ, Pan HF. NLRP3: a promising therapeutic target for autoimmune diseases. Autoimmun Rev. 2018;17(7):694–702.

Article  PubMed  CAS  Google Scholar 

Shi X, Tan S, Tan S. NLRP3 inflammasome in sepsis (review). Mol Med Rep. 2021;24(1):514.

Article  PubMed  CAS  Google Scholar 

He W, Dong H, Wu C, Zhong Y, Li J. The role of NLRP3 inflammasome in sepsis: a potential therapeutic target. Int Immunopharmacol. 2023;115: 109697.

Article  PubMed  CAS  Google Scholar 

Dominic A, Le NT, Takahashi M. Loop between NLRP3 inflammasome and reactive oxygen species. Antioxid Redox Signal. 2022;36(10–12):784–96.

Article  PubMed  CAS  Google Scholar 

Sho T, Xu J. Role and mechanism of ROS scavengers in alleviating NLRP3-mediated inflammation. Biotechnol Appl Biochem. 2019;66(1):4–13.

Article  PubMed  CAS  Google Scholar 

Alfonso-Loeches S, Ureña-Peralta JR, Morillo-Bargues MJ, Oliver-De La Cruz J, Guerri C. Role of mitochondria ROS generation in ethanol-induced NLRP3 inflammasome activation and cell death in astroglial cells. Front Cell Neurosci. 2014;8:216.

Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010;11(2):136–40.

Article  PubMed  CAS  Google Scholar 

Liu Q, Zhang D, Hu D, Zhou X, Zhou Y. The role of mitochondria in NLRP3 inflammasome activation. Mol Immunol. 2018;103:115–24.

Article  PubMed  CAS  Google Scholar 

Yu JW, Lee MS. Mitochondria and the NLRP3 inflammasome: physiological and pathological relevance. Arch Pharm Res. 2016;39(11):1503–18.

Article  PubMed  CAS  Google Scholar 

Zhang T, Ding S, Wang R. Research progress of mitochondrial mechanism in NLRP3 inflammasome activation and exercise regulation of NLRP3 inflammasome. Int J Mol Sci. 2021;22(19):10866.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ma MW, Wang J, Dhandapani KM, Brann DW. NADPH oxidase 2 regulates NLRP3 inflammasome activation in the brain after traumatic brain injury. Oxid Med Cell Longev. 2017;2017:6057609.

Article